Currently, a prospective phase III randomized, double-blind, multicenter trial (NCT02997202) using gilteritinib versus placebo for patients with FLT3-ITD AML as maintenance after allo-HCT is ongoing [59]. Here, FLT3 is linked to acute myeloid leukemia.